|View printer-friendly version|
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
- Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability
- Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo (AM-125) and antipsychotic-induced weight gain (AM-201)
- Detailed results from HEALOS Phase 3 trial with Sonsuvi® published in peer-reviewed journal
- Full repayment of loan facility to result in a significant reduction of interest expense and strengthened balance sheet
- Redomiciliation to
Bermudato reduce costs and better align with U.S. capital market practices
"Following the successful Phase 1 trial for our intranasal betahistine program in 2018, we have been busy preparing two proof-of-concept studies that will initiate soon and from which we expect to obtain interim and final results, respectively, in the second half of 2019," stated
Development Program Updates
AM-125 for Vertigo
- Progressed with preparations for TRAVERS Phase 2 trial with AM-125 in acute vertigo. The TRAVERS trial will enroll 138 patients that suffer from acute vertigo following surgical removal of a vestibular schwannoma, a tumor growing behind the inner ear. The selection of clinical trial sites in several European countries and
Canadahas essentially been completed and the first approval from a competent authority has already been received. In Part A of the TRAVERS trial, five ascending doses of AM-125 or placebo, administered three times daily over a total of four weeks, will be tested in a total of 50 patients. In addition, oral betahistine 48 mg will be tested in 16 patients under open-label conditions for reference. Based on an interim analysis, two doses will be selected and tested in an estimated 72 patients in Part B.
AM-201 for Antipsychotic-Induced Weight Gain
- Progressed with preparations for Phase 1b trial with AM-201 in antipsychotic-induced weight gain. The trial will be conducted at a single trial site in a European country and enroll 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with olanzapine over four weeks. Doses will be escalated in five steps, as in the TRAVERS trial. The trial has been approved by the local ethics committee (institutional review board) and the competent authority and is expected to start recruitment before the end of the first quarter of 2019.
Other developments related to betahistine
- Acquired Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS). PWS is a rare genetic disorder characterized by progressive obesity, behavioral issues, delayed cognition and sleep disturbances. Emerging research suggests positive effects of H3 histamine receptor inhibition on cognitive disability and excessive daytime sleepiness. Betahistine acts as an H3 receptor antagonist and uniquely, also as an agonist at the H1 histamine receptor, which plays a crucial role in the regulation of food intake. The Company acquired the Orphan Drug Designation from its previous holder with the transfer being recorded by the
U.S. Food and Drug Administration( FDA).
- Obtained rights to two U.S. patents relating to treatment of two mental disorders with betahistine. The Company entered into a binding Letter of Intent to acquire exclusive rights to in-license two U.S. patents relating to the use of betahistine for the treatment of atypical depression and attention-deficit / hyperactivity disorder (ADHD). The Company expects to close the transaction in the second quarter of 2019.
- Announced independent evidence for betahistine's role in promoting the retrieval of forgotten memories. In a peer-reviewed article, evidence was presented that betahistine promotes the retrieval of forgotten memories in mice and human beings. Notably it was shown in a study with 38 healthy adult volunteers that treatment with betahistine overall improved the percentage of correct memories (p<0.05), enhanced the retrieval of more difficult items and benefited participants with poor performance under placebo treatment (p<0.01).
Sonsuvi® / AM-111 for Acute Inner Ear Hearing Loss
- Published detailed results from HEALOS Phase 3 trial. The detailed results from HEALOS, a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of AM-111 in 256 patients suffering from severe to profound sudden deafness were published in Otology & Neurotology, one of the leading journals in the field of scientific and clinical inner ear research. While the HEALOS trial did not meet the primary efficacy endpoint in the overall study population, post-hoc analyses revealed a statistically significant hearing improvement with AM-111 from baseline to Day 28 in the subpopulation of patients with profound hearing loss (n=98). The AM-111 0.4 mg/mL treatment group showed a mean improvement of 42.7 dB vs. 26.8 dB in the placebo group (p=0.0176). AM-111 was well-tolerated and the primary safety endpoint was met.
- Continued partnering process for AM-111. As previously announced, the Company decided to refocus its development activities on the intranasal betahistine program and to seek partners or other sources of non-dilutive funding for its late-stage development programs. In this context, the Company initiated a structured partnering process with an international transaction advisory firm to identify potential partners for the AM-111 development program.
Keyzilen® / AM-101 for Acute Inner Ear Tinnitus
- Defined development path for Keyzilen® / AM-101. Given the strong unmet medical need among tinnitus sufferers as well as the positive data obtained with Keyzilen® from non-clinical studies, two Phase 2 trials and the two open label AMPACT trials, the Company has assessed how to address the issues arising from elements in the design and conduct in the unsuccessful TACTT2 and TACTT3 trials and take the program forward. Based on this, the Company has defined a development path forward and is currently exploring options for its implementation through partnering and / or non-dilutive funding.
- Made early repayment of loan facility with
Hercules Capital, Inc.On January 31, 2019, the Company made the final payment to Hercules under the facility, comprising the last amortization rate as well as an end of term charge, 12 months ahead of the original schedule. With the final payment, all covenants and collateral in favor of Hercules have been lifted. The repayment will result in a significant reduction of the Company's interest expense, improve its balance sheet and enhance its financial flexibility.
- Relocating the Company's domicile to
Bermuda. On March 8, 2019, an extraordinary general meeting of shareholders approved with an overwhelming majority the transfer of the Company from Zug, Switzerlandto Hamilton, Bermuda, a related memorandum of continuance and new by-laws under Bermudalaw. The redomiciliation is expected to become effective before the end of March 2019upon registration of the Company with the Registrar of Companies in Bermuda. With the move, the Company expects to gain more corporate flexibility, achieve cost savings and operate under a jurisdiction that is more familiar to U.S. investors.
Fourth Quarter 2018 Financial Results
- Total operating expenses for the fourth quarter of 2018 were
CHF 0.7 millioncompared to CHF 5.4 millionfor the fourth quarter of 2017.
- Research and development expenses for the fourth quarter of 2018 were
CHF 0.03 millioncompared to CHF 4.3 millionfor the fourth quarter of 2017.
- General and administrative expenses for the fourth quarter of 2018 were
CHF 0.6 millioncompared to CHF 1.2 millionfor the fourth quarter of 2017.
- Net loss for the fourth quarter of 2018 was
CHF 3.7 million, or CHF 0.12per share, compared to CHF 4.6 million, or CHF 1.05per share, for the fourth quarter of 2017.
- Cash and cash equivalents at
December 31, 2018, totaled CHF 5.4 million.
Full Year 2018 Financial Results
- Total operating expenses for 2018 were
CHF 11.0 millioncompared to CHF 24.4 millionfor 2017.
- Research and development expenses for 2018 were
CHF 6.7 millioncompared to CHF 19.2 millionfor 2017.3
- General and administrative expenses for 2018 were
CHF 4.3 millioncompared to CHF 5.2 millionfor 2017.
- Net loss for 2018 was
CHF 11.5 million, or CHF 0.72per share, compared to CHF 24.4 million, or CHF 5.58per share, for 2017.
The Company expects that its operating expenses in 2019 will be in the range of
Conference Call & Webcast Information
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss
For the Three and Twelve Months Ended
ENDED DECEMBER 31
ENDED DECEMBER 31
|Research and development||(34,923)||(4,285,200)||(6,689,589)||(19,210,842)|
|General and administrative||(634,869)||(1,153,036)||(4,264,534)||(5,150,409)|
|Foreign currency exchange gain/(loss), net||40,055||104,794||(139,870)||(824,592)|
|Revaluation gain / (loss) from derivative financial instruments||(2,781,791)||1,667,168||1,350,071||3,372,186|
|Loss before tax||(3,502,510)||(4,578,793)||(11,334,224)||(24,427,247)|
|Income tax gain/(loss)||(188,356)||(6,800)||(162,177)||17,773|
|Net loss attributable to owners of the Company||(3,690,866)||(4,585,593)||(11,496,401)||(24,409,474)|
|Other comprehensive income/(loss):|
|Items that will never be reclassified to
profit or loss
|Remeasurement of defined benefit liability||(17,670)||(106,120)||1,277,192||271,980|
|Items that are or may be reclassified to
profit or loss
|Foreign currency translation differences||2,152||(4,819)||(10,964)||50,497|
|Other comprehensive income/(loss)||(15,518)||(110,939)||1,266,228||322,477|
|Total comprehensive loss attributable
to owners of the Company
|Basic and diluted loss per share||(0.12)||(1.05)||(0.72)||(5.58)|
|Average weighted number of shares outstanding, adjusted for effect of reverse stock split||30,427,094||4,374,187||15,900,865||4,374,187|
Condensed Consolidated Statement of Financial Position
|Property and equipment||33,895||252,899|
|Derivative financial instruments||226,865||-|
|Other non-current financial receivables||16,001||76,710|
|Total non-current assets||3,812,001||1,958,709|
|Cash and cash equivalents||5,393,207||14,973,369|
|Total current assets||6,064,864||15,867,563|
|EQUITY AND LIABILITIES|
|Foreign currency translation reserve||(44,011)||(33,047)|
|Total shareholders (deficit)/equity attributable to owners of the Company||3,649,650||(2,162,209)|
|Derivative financial instruments||675,328||1,836,763|
|Deferred tax liabilities||340,986||178,809|
|Total non-current liabilities||1,664,601||9,562,839|
|Trade and other payables||1,836,335||1,200,820|
|Total current liabilities||4,562,614||10,425,642|
|Total equity and liabilities||9,876,865||17,826,272|
 Nomura et al., Central histamine boosts perirhinal cortex activity and restores forgotten object memories, Biol Psychiatry 2019, in press.
 Staecker et al., Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness - A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study, Otol Neurotol 2019, in press.
 Does not include capitalized costs related to expenses for the AM-125 program in accordance with IAS38.
Source: Auris Medical AG